Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Publication | Closed Access

DOI

249

Citations

References

2020

Year

Yi‐Long Wu, Ying Cheng, Jianying Zhou, Shun Lü, Yiping Zhang, Jun Zhao, Dong‐Wan Kim, Ross A. Soo, Sang‐We Kim, Hongming Pan,

The Lancet Respiratory Medicine

OncologyMet AmplificationMedicinePathologyPhase 1B/2Bronchial NeoplasmInsight StudyCancer TreatmentPharmacologyRadiation OncologyLung CancerMolecular OncologyCancer Growth